Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synta Pharmaceuticals, a biopharmaceutical company, has met its target of 630 patients for the Symmetrysm trial - a global, pivotal Phase III clinical trial to evaluate the efficacy and safety of elesclomol in patients with stage IV metastatic melanoma.
Subscribe to our email newsletter
Elesclomol is being developed under a global collaboration agreement between Synta Pharmaceuticals and GlaxoSmithKline and is not approved for marketing by the FDA or any other similar regulatory body in any country.
Safi Bahcall, president and CEO of Synta, said: “Today’s milestone represents a terrific achievement on the part of the full Symmetry team – the Synta employees, physicians, nurses, healthcare professionals and our partners around the world who came together to enroll one of the largest pivotal trials for a new agent in this disease so rapidly and effectively.
“We intend to conduct the primary endpoint analysis with the same attention to detail and high standards of excellence; our goal is to complete this analysis by May 2009. We are hopeful that this effort on the part of so many will translate into a new therapy for patients.”